Taldefgrobep Alfa
An engineered myostatin-binding protein that is not an antibody. It failed in Duchenne muscular dystrophy and then missed its primary endpoint in a phase 3 spinal muscular atrophy trial — but cut body fat significantly in that same trial, which is why Biohaven redirected it to obesity.
Taldefgrobep alfa blocks myostatin, the brake on muscle growth, using an engineered fibronectin-based protein rather than an antibody. It failed in Duchenne muscular dystrophy and then missed its main goal in a phase 3 spinal muscular atrophy trial. In that trial it did significantly cut body fat, which is why it is now being tested in obesity. Nothing about it is approved, and the obesity results are not out yet.
What is Taldefgrobep Alfa?
Taldefgrobep alfa is an engineered recombinant protein designed to block myostatin, the signal that tells skeletal muscle to stop growing. It is not a monoclonal antibody, which sets it apart from every other advanced drug in its class. It is built on an adnectin scaffold — a small binding protein derived from the tenth type III domain of human fibronectin, engineered to bind a chosen target the way an antibody would but at a fraction of the size — and linked to a serum albumin-binding component that extends its time in the body. Its mechanism is also broader than the name suggests. The protein binds active myostatin (GDF-8) and the closely related GDF-11, but the resulting taldefgrobep–myostatin complex then docks onto the activin type II receptor and prevents it recruiting its signalling partners ALK4, ALK5 and ALK7. The consequence is that the drug blocks not only myostatin but other ligands that signal through that receptor, including activins. Its developer now describes it as a myostatin-activin pathway inhibitor rather than a myostatin antibody. Its clinical history is a run of negative results with an interesting residue. Roche developed it in Duchenne muscular dystrophy and stopped after a pre-planned futility analysis showed a lack of efficacy. Biohaven then took it into a phase 3 trial in spinal muscular atrophy, where it again missed its primary endpoint on motor function. But in that trial it produced a statistically significant reduction in body fat, and that single secondary finding is the reason the compound is now in a phase 2 obesity trial rather than on a shelf.
What Taldefgrobep Alfa Is Investigated For
Taldefgrobep alfa has been tested properly in two neuromuscular diseases and failed in both, and it is now being tested in a third indication that grew out of a secondary finding in the second failure. In Duchenne muscular dystrophy, Roche ran a phase 1 study in healthy adults that showed a significant increase in thigh muscle volume, a phase 1b/2 safety study in ambulatory boys, and a phase 2/3 trial of 166 boys with the North Star Ambulatory Assessment as the primary endpoint. The phase 2/3 trial did not meet the pre-specified futility threshold, and both ongoing Duchenne studies were discontinued as a result. Myostatin suppression itself was never in doubt — dosing produced robust, dose-dependent suppression of free myostatin, and effects on lean body mass were real but modest. The drug engaged its target and the target did not deliver the function. In spinal muscular atrophy, Biohaven ran RESILIENT, a phase 3 placebo-controlled trial of taldefgrobep added on top of SMN-targeted therapy, with change in the 32-item Motor Function Measure at week 48 as the primary endpoint. The treatment arm did not statistically separate from placebo on that endpoint. The company reported sub-analyses that did reach significance — in the predominantly Caucasian study population and in the subgroup with measurable baseline myostatin — but these are subgroup findings inside a trial that missed, and they should be read as hypothesis-generating. The body-composition result from RESILIENT is what survived. Treated participants showed a significantly greater reduction in the percent change in total body fat mass than placebo on DXA, with numerically larger increases in lean muscle mass and bone density. A drug that reduces fat and nudges lean mass upward is a plausible partner for incretin weight-loss therapy, where a substantial fraction of the weight lost is lean tissue, and a phase 2 obesity trial is now running on exactly that thesis — with results not yet public.
History & Discovery
Taldefgrobep alfa began at Bristol Myers Squibb as BMS-986089, part of a wave of myostatin-pathway programmes that followed the discovery that animals and people lacking functional myostatin develop extraordinary muscle mass. The adnectin platform it is built on came to Bristol Myers Squibb through its acquisition of Adnexus, and the format was chosen for the usual reasons — a small, stable, fully human scaffold that can be engineered for high-affinity binding without antibody manufacturing. Roche took the molecule into Duchenne muscular dystrophy under the code RO7239361, running a phase 1b/2 safety study in ambulatory boys and a phase 2/3 trial of 166 boys with the North Star Ambulatory Assessment as the primary endpoint. The programme ended abruptly: a pre-planned futility analysis in the larger study indicated a lack of efficacy, and Roche discontinued both ongoing Duchenne studies. The registry record for the smaller study states the reason plainly. Biohaven acquired the compound and redirected it to spinal muscular atrophy, where the rationale was arguably stronger — SMN-targeted therapies had transformed survival and motor outcomes but left patients with persistent muscle weakness, so a muscle-directed add-on addressed a real gap. RESILIENT enrolled through September 2023 and completed its primary assessment in September 2024. Topline results came in November 2024: the primary endpoint was not met. The company's response was to pivot rather than stop, and the reason was the body-composition data. RESILIENT had measured DXA, and the fat-mass reduction it found was statistically significant. Biohaven began describing the molecule as a myostatin-activin pathway inhibitor for overweight and obesity, presented supporting adipocyte and obese-mouse work at ObesityWeek in 2024 and 2025, and started a phase 2 obesity trial in November 2025. That trial completed enrolment in 2026 with topline results guided to the second half of the year. As of this writing they have not been published, and the compound's entire future rests on them.
How It Works
Muscle growth has a built-in brake called myostatin: the more of it circulating, the less muscle the body builds. Taldefgrobep is a small engineered protein that grabs myostatin and holds on. The twist is what happens next — the pair then sits on the receptor that myostatin would have activated and blocks it, so other related signals, including activins, cannot get through either. Releasing that brake makes muscle grow, and in fat cells the same blocked signal appears to reduce fat storage and increase the activity of the cell's energy-burning machinery. That dual effect on muscle and fat is why a failed muscle-disease drug became an obesity candidate.
Taldefgrobep alfa is a recombinant fusion protein combining an adnectin — an engineered binding domain derived from the tenth type III domain of human fibronectin — with an albumin-binding component that extends its circulating half-life. The adnectin binds active myostatin (GDF-8) and the closely related ligand GDF-11 with high affinity. The pharmacology does not stop at ligand sequestration, which is what distinguishes it from a conventional anti-myostatin antibody. Per its developer's own mechanistic work, the taldefgrobep–myostatin complex binds the activin type II receptor and prevents the recruitment of the type I receptors ALK4, ALK5 and ALK7 that would normally be required to transduce the signal. Because the activin type II receptor is the shared entry point for several TGF-beta superfamily ligands, blocking its assembly inhibits signalling by activins as well as by myostatin itself. The downstream consequence is reduced phosphorylation of SMAD2 and SMAD3, which is the transcriptional pathway through which this ligand family suppresses muscle growth. In skeletal muscle, relieving that suppression produces hypertrophy — the long-established consequence of myostatin pathway blockade and the effect that drove the Duchenne and spinal muscular atrophy programmes. In adipose tissue the picture the developer has presented is different and is the basis of the obesity rationale: taldefgrobep reduced phospho-SMAD2/3 signalling in both mouse 3T3-L1 adipocytes and primary human adipocytes, reduced intracellular lipid storage, and increased mitochondrial mass and basal oxygen consumption. In an obese mouse model, both as monotherapy and in combination with semaglutide, it reduced fat mass and increased lean mass. This adipocyte work is preclinical and company-generated; the human evidence for a fat effect rests on the DXA findings from RESILIENT. The translational problem this compound illustrates is one the whole class shares. Target engagement has never been the difficulty — taldefgrobep produced robust, dose-dependent suppression of free myostatin in Duchenne trials and drove myostatin below detection for 48 weeks in the spinal muscular atrophy trial. Converting that engagement into functional benefit is what has repeatedly failed.
Evidence Snapshot
Human Clinical Evidence
Substantial, and mostly negative. In Duchenne muscular dystrophy: a phase 1 study in healthy adults showing significantly increased thigh muscle volume, a phase 1b/2 safety study in ambulatory boys (n=43), and a phase 2/3 trial (n=166) whose results did not meet the pre-specified futility threshold on the North Star Ambulatory Assessment, leading Roche to discontinue both ongoing Duchenne studies. In spinal muscular atrophy: RESILIENT, a phase 3 placebo-controlled add-on trial, where the treatment arm did not statistically separate on the primary endpoint of MFM-32 change at week 48, but produced a significantly greater reduction in percent change in total body fat mass (p=0.008 by DXA). In obesity: a phase 2 dose-ranging trial of weekly and four-weekly dosing against placebo, with percent change in body weight at week 24 as the primary endpoint, fully enrolled and not yet reported.
Animal / Preclinical
Consistent and supportive. Preclinical studies demonstrated significant decreases in myostatin and increased lower limb volume across three animal species including dystrophic mice. In diet-induced obese mice, taldefgrobep reduced fat mass and increased lean mass both alone and combined with semaglutide. Cell-based work in mouse and primary human adipocytes shows reduced SMAD2/3 phosphorylation, reduced lipid storage and increased mitochondrial mass.
Mechanistic Rationale
Strong on the biology, weak as a predictor of benefit. Myostatin's role as a negative regulator of muscle mass is among the best-established facts in muscle biology, and taldefgrobep demonstrably suppresses it. The repeated failure of functional endpoints across this entire drug class is the reason mechanistic plausibility cannot be treated as evidence of efficacy here.
Research Gaps & Open Questions
What the current literature has not yet settled about Taldefgrobep Alfa:
- 01Whether the obesity phase 2 confirms the body-composition signal. The entire case for this compound now rests on a secondary DXA endpoint from a trial that failed its primary, tested in a disease population, being reproducible in people with obesity. Results were guided for the second half of 2026 and are not yet public.
- 02Whether the myostatin-positive subgroup finding in RESILIENT is real. It is biologically coherent that a myostatin blocker works better in people with measurable myostatin, and if true it would imply the whole class has been diluted by treating patients who had little target to block. It is also exactly the kind of post-hoc-flavoured subgroup that fails to replicate.
- 03Why target engagement keeps failing to produce function. Taldefgrobep suppressed myostatin below detection for 48 weeks and did not improve motor outcomes; domagrozumab, bimagrumab and ACE-031 produced comparable disconnects. Whether the explanation is denervation, neuromuscular junction integrity, the wrong patient populations, or the wrong endpoints is unresolved and matters more than any single compound.
- 04What blocking activins alongside myostatin does over years. The drug-myostatin complex inhibits activin signalling through the activin type II receptor, a broader intervention than anti-myostatin antibodies, with potential consequences for reproduction, erythropoiesis, bone and tumour biology that no trial has been designed or sized to detect.
- 05Whether four-weekly dosing is sufficient. The obesity trial tests weekly against four-weekly administration, and the answer would materially affect the compound's practical appeal, but no pharmacodynamic bridging data have been published.
- 06Whether combination with an incretin works in humans. The mouse data with semaglutide are supportive and the commercial logic is obvious, but the human phase 2 is monotherapy, so the combination most likely to be commercialised is the one least tested.
Forms & Administration
Subcutaneous injection. Dose-ranging in the Duchenne programme went up to 50 mg weekly. The obesity phase 2 is testing both once-weekly and once-every-four-weeks administration, self-administered by autoinjector, which reflects the half-life extension conferred by the albumin-binding component. There is no approved formulation and no supply outside clinical trials. All investigational biologics are administered under the supervision of trial investigators, and nothing sold under this name through consumer channels is the clinical compound.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
No approved dose exists. Duchenne dose-ranging went up to 50 mg weekly by subcutaneous injection. The obesity phase 2 tests undisclosed doses on two schedules — once weekly and once every four weeks — against matching placebo.
Frequency
Weekly subcutaneous in the neuromuscular programmes. The obesity trial is testing weekly and four-weekly dosing in parallel, which is itself an open question the trial is designed to answer.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
The spinal muscular atrophy trial ran 48 weeks; the obesity trial's primary endpoint is at 24 weeks. There is no established treatment duration because there is no approved use.
Protocol Notes
Nothing here constitutes a protocol, and there is no scenario in which taldefgrobep is self-administered. It is worth understanding why the dosing interval is a real scientific question rather than a convenience one: the albumin-binding component gives the molecule a long residence time, and the obesity trial is testing whether a monthly injection holds the pathway suppressed as well as a weekly one. For a chronic body-composition therapy, a four-weekly schedule would be a meaningful practical advantage over the weekly and daily injections that dominate the metabolic field. The other dosing lesson from this programme is that more target engagement did not buy more benefit. Taldefgrobep suppressed free myostatin robustly and dose-dependently in Duchenne, and drove myostatin below detection for 48 weeks in spinal muscular atrophy, and neither trial met its endpoint. Dose escalation is not the unexplored lever it might appear to be.
Taldefgrobep alfa is investigational, has failed two efficacy programmes, and is not approved or available anywhere. This section describes trial dosing for understanding only, not for use.
Timeline of Effects
Onset
Myostatin suppression is rapid and dose-dependent after subcutaneous dosing — this was consistent across the Duchenne studies. Downstream changes in muscle or fat are far slower: the healthy-volunteer study measured increased thigh muscle volume over weeks, and the trials that assessed function or body composition did so at 24 to 48 weeks.
Peak Effect
Not established. Both completed efficacy trials measured their primary outcomes at a fixed endpoint — week 48 in spinal muscular atrophy, week 48 in the Duchenne phase 2/3 — rather than identifying a plateau, and the obesity trial reads out at week 24. Because myostatin suppression was maintained below detection across 48 weeks without a corresponding functional gain, the limiting factor is clearly not the depth or duration of target engagement.
After Discontinuation
Not characterised in any published report. Myostatin levels would be expected to recover as the drug clears, and any muscle or fat changes to reverse over the following months, but no trial has published off-treatment follow-up to confirm that.
Common Questions
What is an adnectin, and why does it matter here?
An adnectin is a binding protein engineered from the tenth type III domain of human fibronectin — a small, stable human scaffold whose surface loops can be reshaped to grip a chosen target, much as an antibody's loops do. The practical differences from an antibody are size and structure: an adnectin is roughly a tenth the size, has no Fc region and no glycosylation, and is made in bacterial rather than mammalian systems. For taldefgrobep the format matters less than what the molecule does once bound, which is unusual: rather than simply mopping up myostatin, the drug–myostatin complex engages the activin type II receptor and blocks other ligands from signalling through it. That makes it a broader pathway inhibitor than a pure anti-myostatin antibody, which may matter for both effect and side-effect profile.
Why did taldefgrobep fail in spinal muscular atrophy?
On the trial's own terms, it simply did not beat placebo. RESILIENT measured change in the 32-item Motor Function Measure at 48 weeks in participants already receiving an SMN-targeted therapy, and the treatment arm did not statistically separate on that endpoint. Biohaven highlighted analyses that did reach significance — one in the predominantly Caucasian study population and one in the subgroup of participants who had measurable myostatin at baseline — and both are worth knowing about, because a myostatin drug plausibly cannot work in someone with little myostatin to block. But a subgroup that reaches p<0.05 inside a trial whose primary endpoint failed is a hypothesis, not a result. The wider pattern across this drug class is that suppressing myostatin and improving function have repeatedly turned out to be different things.
If it failed twice, why is it being tested in obesity?
Because of one secondary finding. In RESILIENT, participants on taldefgrobep showed a significantly greater reduction in percent change in total body fat mass than those on placebo, measured by DXA, with numerically larger gains in lean muscle mass and bone density. That is a body-composition signal from a well-controlled 48-week trial in humans, generated while the drug was failing at something else. It lands in a moment when the central criticism of incretin weight-loss drugs is that a meaningful share of the weight they remove is lean tissue, so an agent that shifts the fat-to-lean ratio has an obvious role as an add-on. The obesity phase 2 is testing taldefgrobep on its own, not alongside an incretin, with percent change in body weight at week 24 as the primary endpoint.
Is taldefgrobep the same thing as the drugs that preserve muscle during weight loss?
It is in the same class but at a different stage and with a different mechanism detail. Apitegromab, the only approved myostatin-pathway drug, binds pro- and latent myostatin before activation and is approved for spinal muscular atrophy, not for body composition. Trevogrumab and bimagrumab are antibodies — trevogrumab against myostatin, bimagrumab against the activin II receptor itself — and both have been studied alongside incretins specifically to preserve lean mass. Taldefgrobep is the non-antibody in the group, and the only one whose body-composition evidence came out of a failed neuromuscular trial rather than a purpose-built obesity study. None of the four is approved for weight management.
Can I get taldefgrobep?
No. It has never been approved in any country for any indication, and the only legitimate way anyone has received it is inside a clinical trial. More than 700 people have been treated with it across its development programmes, which is a reasonable safety database by investigational standards, but that exposure happened under trial conditions. Products marketed as myostatin inhibitors through research-chemical or peptide-marketplace channels are not this molecule, and an engineered albumin-binding adnectin is not something a grey-market supplier produces.
Who Taldefgrobep Alfa Is NOT For
- •Any use outside a clinical trial — there is no approved product, no verified supply and no established dose.
- •Pregnancy and breastfeeding — the drug binds GDF-11 as well as myostatin, and GDF-11 has developmental roles; no reproductive safety data exist.
- •Paediatric use outside the neuromuscular trial setting in which it was specifically studied.
- •Any expectation of use as a performance or physique agent — the class is explicitly prohibited in sport and the functional benefits have repeatedly failed to materialise even in disease populations where they were most plausible.
- •Known hypersensitivity to the product or its components, as for any recombinant protein therapeutic.
Drug & Supplement Interactions
No drug-interaction studies have been published for taldefgrobep alfa, and as a recombinant protein cleared by proteolysis rather than cytochrome P450 metabolism it is not expected to produce classical pharmacokinetic interactions. The interactions that matter are pharmacodynamic and mostly prospective. In spinal muscular atrophy the drug was given as an add-on to SMN-targeted therapies — nusinersen, risdiplam or onasemnogene abeparvovec — and that combination was the trial design rather than an interaction concern. In obesity the combination that matters is with incretin therapy: the entire commercial thesis for myostatin-pathway agents in weight management is as a partner to GLP-1 or dual-agonist drugs, preserving lean mass while the incretin drives weight loss. Taldefgrobep has been combined with semaglutide in obese mice with additive effects on body composition, but the ongoing phase 2 is a monotherapy study, so no human combination data exist for this compound. Stacking taldefgrobep with another agent acting on the same pathway — an anti-myostatin antibody, an activin receptor blocker, or follistatin-based products sold in grey-market channels — has no evidence base and no rationale, since the pathway can only be blocked once. Corticosteroids, which were background therapy in the Duchenne trials, have their own catabolic effects on muscle; how that interaction plays out was not isolated in any published analysis.
Safety Profile
Common Side Effects
Cautions
- • Investigational — no approval anywhere, and two failed efficacy programmes behind it
- • Blocks more than myostatin: the drug-myostatin complex inhibits activin signalling through the activin II receptor, a broader intervention whose long-term consequences are not characterised
- • No published long-term data in healthy or obese adults; the longest controlled exposure is 48 weeks in a disease population
- • The obesity programme is reporting into a field where a related mechanism, activin receptor blockade with bimagrumab, has raised tolerability questions
- • No pregnancy, lactation or paediatric safety data outside the muscular dystrophy programmes
What We Don't Know
The safety record is unusual in shape: a relatively large exposure base across Duchenne, spinal muscular atrophy and now obesity, but little of it published in the detail that would let an outside reader judge it. What a body-composition drug most needs — long-term data in otherwise healthy adults, effects on bone, cardiac and smooth muscle, reproductive endocrinology given the GDF-11 and activin crossover, and what happens when the drug is stopped after prolonged use — is essentially absent. The GDF-11 question deserves particular attention, because that ligand has roles beyond skeletal muscle and the drug binds it alongside myostatin by design.
Legal Status
United States
Not FDA-approved for any indication. Taldefgrobep alfa is an investigational biologic that failed its phase 2/3 programme in Duchenne muscular dystrophy and missed its primary endpoint in phase 3 in spinal muscular atrophy; after the latter, the developer said it planned to engage the FDA about potential next steps. It is currently in phase 2 for overweight and obesity. It is not a controlled substance, has no prescription availability, and no compounded or research-chemical product is this molecule.
International
Not approved by the EMA, the UK MHRA, Health Canada, the TGA, Japan's PMDA or any other regulator. Development has been conducted by Bristol Myers Squibb, then Roche in Duchenne muscular dystrophy, and latterly Biohaven in spinal muscular atrophy and obesity.
Sports & Competition
Prohibited at all times. Myostatin-pathway agents are explicitly captured by WADA's section S4.3, which prohibits agents preventing activin receptor IIB activation, including myostatin-neutralising antibodies, myostatin-binding proteins and myostatin inhibitors. Taldefgrobep alfa is a myostatin-binding protein that blocks activin type II receptor signalling, which places it inside that entry by description rather than by name — the list names follistatin and myostatin propeptide as examples of myostatin-binding proteins, and bimagrumab and apitegromab elsewhere in the same entry. Substances in S4.3 are non-Specified. Note that S0, which catches unapproved investigational drugs, does not apply here: S0 covers only substances not addressed by a later section of the list, and S4.3 addresses this one.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Taldefgrobep is a myostatin antibody.
Reality
It is not an antibody at all. It is an adnectin — an engineered binding protein derived from a human fibronectin domain — fused to an albumin-binding component. It also does more than bind myostatin: the drug-myostatin complex docks on the activin type II receptor and blocks the recruitment of ALK4, ALK5 and ALK7, which inhibits activin signalling as well. Its developer now calls it a myostatin-activin pathway inhibitor rather than a myostatin antibody, and that distinction has real implications for what else the drug might affect.
Myth
The RESILIENT trial showed taldefgrobep works in spinal muscular atrophy.
Reality
The trial missed. In the company's own regulatory filing, the treatment arm did not statistically separate on the primary outcome at week 48. The significant results reported alongside that statement are subgroup analyses — in the predominantly Caucasian study population and among participants with measurable baseline myostatin. Those are reasons to run another trial, not evidence of efficacy, and the point estimates quoted in news coverage of the topline differ from one another and do not appear in the filing at all.
Myth
Myostatin inhibitors build muscle, so taldefgrobep failed only because the trials were badly designed.
Reality
Taldefgrobep increased thigh muscle volume in healthy volunteers and suppressed myostatin below detection for a year in patients, so the pharmacology worked. What did not follow was functional benefit, and that disconnect has now repeated across domagrozumab, bimagrumab, ACE-031 and taldefgrobep in several different diseases. When an entire class produces mass without function, the most likely explanation is biological rather than a run of bad trial design.
Myth
It is now an obesity drug.
Reality
It is an obesity candidate in phase 2, with no published human obesity results. The evidence behind the pivot is a secondary body-composition endpoint from a failed trial in a neuromuscular disease, plus preclinical adipocyte and mouse work generated by the developer. That is a reasonable basis for running a trial and not a basis for concluding anything about how it performs in people with obesity.
Myth
You can buy taldefgrobep or an equivalent from a peptide supplier.
Reality
No. It is a recombinant fusion protein with an engineered fibronectin-derived binding domain and an albumin-binding element — not a synthesisable short peptide, and not something produced outside a biologics manufacturing process. Products sold as myostatin inhibitors, myostatin blockers or follistatin in grey-market channels are different substances entirely, and the class is prohibited in sport at all times.
Published Research
10 studiesAdvancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway
Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy
International Journal of Molecular Sciences 2024, the design paper for RESILIENT, published before the trial reported. It describes taldefgrobep as a fully human recombinant protein that selectively binds myostatin and competitively inhibits other ligands signalling through the activin II receptor, and sets out the rationale for combining myostatin inhibition with SMN upregulation as a whole-motor-unit strategy. Useful as the clearest statement of what the trial set out to do, and worth reading against what it found.
Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy
The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy
Neurology and Therapy 2024, the cumulative report of the three Duchenne trials. In healthy adult volunteers taldefgrobep was generally well tolerated and significantly increased thigh muscle volume; in ambulatory boys it produced robust dose-dependent suppression of free myostatin with a positive but modest effect on lean body mass; and the phase 2/3 trial's effects did not meet the pre-specified futility threshold on the North Star Ambulatory Assessment. The honest summary of a programme in which target engagement succeeded and function did not.
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT, NCT05337553)
Taldefgrobep Alfa in Adults With Overweight and Obesity (NCT07281495)
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy (NCT03039686)
Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD (NCT02515669)
Biohaven Ltd. Annual Report on Form 10-K for the fiscal year ended December 31, 2024
The primary source for what RESILIENT actually showed, in language reviewed by the company's lawyers rather than its communications team. It states that the treatment arm did not statistically separate on the primary outcome at week 48, while reporting improvements on the MFM-32 in the largest study population (87% Caucasian, n=180) at p<0.05, an improved efficacy signal in the 123 participants with measurable baseline myostatin (p=0.02), and a greater reduction in percent change in total body fat mass by DXA (p=0.008) with numerically larger increases in lean muscle mass and bone density. Point estimates for the MFM-32 difference circulating in press coverage do not appear in the filing.
Taldefgrobep/Myostatin Complex Inhibits TGF-beta Ligand Signaling Reducing Lipid Storage in Adipocytes (ObesityWeek 2025)
Biohaven's own mechanistic presentation, and the clearest published statement of how the drug works. Taldefgrobep binds active myostatin and GDF-11; the resulting complex binds the activin II receptor and prevents recruitment of ALK4, ALK5 and ALK7, inhibiting signalling by activins as well. In adipocytes it reduced phospho-SMAD2/3, reduced lipid storage and increased mitochondrial mass and oxygen consumption; in obese mice it reduced fat mass and increased lean mass alone and with semaglutide. Company-generated preclinical data supporting a commercial thesis, and should be read as such.
Quick Facts
- Class
- Myostatin Pathway Inhibitor
- Tier
- C
- Evidence
- Moderate
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 10PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.